Generate Biomedicines (NASDAQ:GENB) Stock Price Down 5.2% – Time to Sell?

Generate Biomedicines Inc (NASDAQ:GENB) traded down 5.2% during mid-day trading on Tuesday . The stock traded as low as $13.77 and last traded at $13.78. 338,491 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 519,221 shares. The stock had previously closed at $14.53.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GENB. Cantor Fitzgerald began coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating on the stock. Zacks Research raised Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. The Goldman Sachs Group began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price objective for the company. HC Wainwright lifted their target price on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Guggenheim began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $30.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Price Performance

The stock has a 50-day moving average of $13.03.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.